CNS Pharmaceuticals, Inc. (CNSP)

CNS Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	6.46	0.55	10.06	5	14.04
Cash & Short-Term Investments	6.46	0.55	10.06	5	14.04
Cash Growth	1077.53%	-94.54%	100.93%	-64.35%	93.88%
Other Receivables	0.88	-	-	-	-
Receivables	0.88	-	-	-	-
Prepaid Expenses	1.29	0.84	2.51	2.47	1.46
Other Current Assets	0.02	0.2	-	-	-
Total Current Assets	8.66	1.59	12.56	7.48	15.5
Property, Plant & Equipment	0.01	0	0.01	0.02	0.02
Long-Term Deferred Charges	-	-	-	0.33	0.33
Other Long-Term Assets	0.04	0.1	0.48	0.93	-
Total Assets	8.7	1.7	13.05	8.76	15.85
Accounts Payable	2.2	5.83	4.51	1.98	0.95
Accrued Expenses	-	-	-	0.22	0.52
Short-Term Debt	0.33	0.3	0.41	0.39	0.44
Total Current Liabilities	2.52	6.13	4.92	2.59	1.91
Total Liabilities	2.52	6.13	4.92	2.59	1.91
Common Stock	0	0	0	0	0.02
Additional Paid-In Capital	90.6	65.13	58.85	41.6	34.87
Retained Earnings	-84.42	-69.57	-50.72	-35.44	-20.95
Shareholders' Equity	6.18	-4.43	8.13	6.16	13.95
Total Liabilities & Equity	8.7	1.7	13.05	8.76	15.85
Total Debt	0.33	0.3	0.41	0.39	0.44
Net Cash (Debt)	6.14	0.25	9.65	4.62	13.6
Net Cash Growth	2374.76%	-97.43%	108.92%	-66.05%	87.81%
Net Cash Per Share	16.05	-	-	-	-
Filing Date Shares Outstanding	2.94	-	-	-	-
Total Common Shares Outstanding	1.41	-	-	-	-
Working Capital	6.13	-4.54	7.64	4.88	13.59
Book Value Per Share	4.37	-	-	-	-
Tangible Book Value	6.18	-4.43	8.13	6.16	13.95
Tangible Book Value Per Share	4.37	-	-	-	-

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q